In contrast to other abnormally misfolded proteins that accumulate in the nervous system and are associated with its degeneration (e.g., tau in Alzheimer disease and progressive supranuclear palsy, TDP-43 in amyotrophic lateral sclerosis and frontotemporal dementia, or huntingtin in Huntington disease), alpha-synuclein is one of the few that accumulates in the autonomic nervous system, centrally and peripherally, causing generalized autonomic failure, one of the most disabling non-motor features of Parkinson disease (PD) and other synucleinopathies. Among the best-known and better described features of synuclein-mediated autonomic failure is neurogenic orthostatic hypotension (nOH), which results from inappropriate norepinephrine release from efferent sympathetic postganglionic fibers innervating the blood vessels when standing up. The increasing attention to nOH is well deserved given its significant morbidity and the availability of FDA-approved therapies [10] . Autonomic failure in the synucleinopathies, though, affects organs and systems other than the blood vessels, including the heart, the skin and sweat glands, and the gastrointestinal and genitourinary systems.
This issue of Clinical Autonomic Research aims to bring attention to manifestations of autonomic failure in the synucleinopathies other than nOH by putting together original contributions, review articles, and editorial comments from a dazzling group of world-renowned experts in the field.
The issue begins with the Streeten Lecture that Dr. Eduardo Benarroch gave at the 2019 meeting of the American Autonomic Society [1] . Dr. Benarroch highlights how multiple system atrophy (MSA), the most aggressive of the synucleinopathies, preferentially targets the brainstem, thus affecting not just cardiovascular but also respiratory and arousal/sleep functions, which are crucial for survival.
In their state-of-the-art review, Sklerov and colleagues summarize the use of advance functional neuroimaging to further understand the central autonomic network in the synucleinopathies [13] . The review is accompanied by an introductory comment by Prof. Vaughan Macefield, a pioneer in the use of functional neuroimaging in autonomic medicine [9] .
Continuing with neuroimaging, but this time of the heart, Brandle and Braune [2] show that, because cardiac sympathetic denervation is virtually universal in patients with PD, using cardiac MIBG improves the diagnostic accuracy for PD of clinical diagnostic examination alone. MIBG is widely available in Europe but is regrettably much less performed in the US, mostly for insurance reasons. Works like this should contribute to advocate for the use of MIBG for the differential diagnosis of parkinsonism in the US.
An increasingly relevant topic is the detection of alphasynuclein in skin nerves. Skin biopsy is relatively little invasive (as compared to other biomarkers sources, such as CSF analysis) and there is mounting interest by multiple research groups to define if it can improve the diagnostic accuracy of the synucleinopathies. Dr. Vincenzo Donadio, a pioneer in synuclein detection in skin, writes an authoritative review summarizing the advances in this technique, emphasizing the existing challenges [6] . A comment by Dr. Lola Vilas, an expert in alpha-synuclein detection in peripheral tissues [15] , introduces Donadio's review.
Isonaka, Goldstein and colleagues combine the techniques of alpha-synuclein detection in skin biopsy and cardiac 18F-dopamine neuroimaging to show a tight correlation between alpha-synuclein deposition in arrector pilli muscles and cardiac noradrenergic deficits in patients with synucleinopathies [8] . This work is certainly exceptional: Goldstein's group is one of the few in the world with access to cardiac 18F-dopamine neuroimaging to quantify cardiac sympathetic innervation.
Drooling is an under-recognized complain in patients with synucleinopathies. In a large cross-sectional study in Chinese patients with MSA, Yanming and colleagues showed that drooling is present in up to 60% of patients with MSA, and it is associated with more advanced markers of disease progression [4] . Increased recognition of drooling should result in improved therapeutic options for patients with this debilitating symptom.
In spite of their limitations, heart rate variability is still extensively used to understand vagal and baroreflex tone. Carricarte Naranjo and colleagues performed advanced HRV analysis in patients with PD and carriers with the mutations in the gene most commonly affected in the disease, LRRK2 [3] . Interestingly, mutations in this gene have been also found in some patients with PSP and, more recently, in patients with MSA [11, 16] . This has therapeutic implications because therapies targeting LRRK2 are now in the pipeline [17] .
Deep brain stimulation (DBS) has been used for decades to improve motor dysfunction in patients with PD. Although the most common target of the DBS is the subthalamic nucleus, the pedunculopontine nucleus (PPN) is emerging as area of interest. In their innovative work, Green and colleagues showed that stimulation of the PPN might be associated with cardiovascular changes [7] . Although their sample size is small and further studies are required, their results are encouraging and may represent a novel therapeutic avenue for baroreflex dysfunction in patients with synucleinopathies.
Finally, Sakakibara and colleagues focus on bladder and bowel disturbances in the synucleinopathies. In a significant work, they describe a series of patients with MSA whose first manifestation of the disease was bladder dysfunction [12] . This has diagnostic implications, particularly that improved diagnostic criteria for MSA are underway [14] . Finally, in a second work, they studied, for the first time, gastric emptying in patients with dementia with Lewy bodies [5] . Not surprisingly, they found that gastrointestinal emptying was more impaired in DLB compared to PD, highlighting the more aggressive nature of this atypical parkinsonian syndrome.
The editors of Clinical Autonomic Research hope that this issue fulfills its goals of raising awareness of and contributing to the knowledge of dysautonomia in the synucleinopathies, beyond blood pressure abnormalities, with the ultimate objective of improving the patients' quality of life.
